Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Arix Bioscience, a prominent player in the research and development services sector, is headquartered in Great Britain. Founded in 2016, the company has quickly established itself as a leader in the life sciences industry, focusing on the development of innovative therapies and technologies. Arix Bioscience operates primarily in the UK and Europe, leveraging its expertise to support early-stage biotechnology companies.
The firm is renowned for its unique approach to investment and development, providing not only capital but also strategic guidance to its portfolio companies. Arix's commitment to advancing healthcare solutions has positioned it as a key contributor to the biotech landscape, with notable achievements in fostering groundbreaking research. Through its dedication to innovation, Arix Bioscience continues to shape the future of medical science.
-12 vs industry average
Arix Bioscience’s score of 21 is lower than 40% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has typical carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
Arix Bioscience, a UK-based research and development services company, reported total gross carbon emissions of approximately 13,300 kg CO2e in 2022. This includes Scope 1 emissions of 3,680 kg CO2e, Scope 2 emissions (market-based) of 8,890 kg CO2e, and Scope 3 emissions of 5,210 kg CO2e.
Looking back, in 2021, their total gross emissions were approximately 10,430 kg CO2e, comprising Scope 1 emissions of 4,860 kg CO2e, Scope 2 emissions (market-based) of 7,800 kg CO2e, and Scope 3 emissions of 2,900 kg CO2e. In 2020, Arix Bioscience reported Scope 1 emissions of 5,020 kg CO2e and Scope 2 emissions (market-based) of 5,110 kg CO2e. The company aims for a 40% reduction in carbon emissions by 2025 against a 2019 baseline, normalised to occupied areas.
No climate goals have been disclosed for Arix Bioscience yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more